Actively Recruiting
Randomized Study of Rapamycin Versus Placebo for Drug Resistant Epilepsy in Tuberous Sclerosis Complex
Led by Katarzyna Kotulska · Updated on 2026-10-22
200
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of rapamycin compared to placebo in treating drug-resistant epilepsy associated with tuberous sclerosis complex TSC. This is a randomized, double-blind, placebo-controlled Phase 3 study involving children and adults up to age 50 who have a confirmed diagnosis of TSC and ongoing seizures despite treatment. The study aims to determine if rapamycin can reduce the frequency of seizures and assess related side effects. Participants will be randomly assigned to receive either rapamycin or a placebo in liquid form. Dosages of rapamycin are individually calculated based on each participants body surface area. The study includes three main phases an initial screening, a dose adjustment blinded phase, and a core blinded treatment phase. After these, there is an open-label observation period where all participants may be monitored. During the study, participants will have regular assessments to track seizure frequency and any adverse events. The main outcome measured is the proportion of patients who achieve at least a 50% reduction in weekly seizures by the end of the core treatment phase compared to screening. Safety is monitored by recording adverse events during the double-blind phase. The total duration of participation varies according to these study phases, with close monitoring throughout the treatment and observation periods.
CONDITIONS
Brief Title
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
Research Team
K
Katarzyna Kotulska-Jozwiak
M
Monika Szkop
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here